References
1. Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z. Migraine is
first cause of disability in under 50s: will health politicians now take
notice? J Headache Pain. 2018;19(1):17.
2. de Vries T, Villalon CM, MaassenVanDenBrink A. Pharmacological
treatment of migraine: CGRP and 5-HT beyond the triptans.Pharmacol Ther. 2020;211:107528.
3. Disease GBD, Injury I, Prevalence C. Global, regional, and national
incidence, prevalence, and years lived with disability for 310 diseases
and injuries, 1990-2015: a systematic analysis for the Global Burden of
Disease Study 2015. Lancet. 2016;388(10053):1545-1602.
4. Burch RC, Buse DC, Lipton RB. Migraine: Epidemiology, Burden, and
Comorbidity. Neurol Clin. 2019;37(4):631-649.
5. Agosti R. Migraine Burden of Disease: From the Patient’s Experience
to a Socio-Economic View. Headache. 2018;58 Suppl 1:17-32.
6. Hawkins K, Wang S, Rupnow M. Direct cost burden among insured US
employees with migraine. Headache. 2008;48(4):553-563.
7. Leonardi M, Raggi A. A narrative review on the burden of migraine:
when the burden is the impact on people’s life. J Headache Pain.2019;20(1):41.
8. De Matteis E, Guglielmetti M, Ornello R, Spuntarelli V, Martelletti
P, Sacco S. Targeting CGRP for migraine treatment: mechanisms,
antibodies, small molecules, perspectives. Expert Rev Neurother.2020;20(6):627-641.
9. Alasad YW, Asha MZ. Monoclonal antibodies as a preventive therapy for
migraine: A meta-analysis. Clin Neurol Neurosurg.2020;195:105900.
10. Raffaelli B, Mussetto V, Israel H, Neeb L, Reuter U. Erenumab and
galcanezumab in chronic migraine prevention: effects after treatment
termination. J Headache Pain. 2019;20(1):66.
11. Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY.
Efficacy and safety of galcanezumab for the prevention of episodic
migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical
trial. Cephalalgia. 2018;38(8):1442-1454.
12. Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK.
Galcanezumab in chronic migraine: The randomized, double-blind,
placebo-controlled REGAIN study. Neurology.2018;91(24):e2211-e2221.
13. Goadsby PJ, Reuter U, Hallstrom Y, et al. A Controlled Trial of
Erenumab for Episodic Migraine. N Engl J Med.2017;377(22):2123-2132.
14. Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab
for preventive treatment of chronic migraine: a randomised,
double-blind, placebo-controlled phase 2 trial. Lancet Neurol.2017;16(6):425-434.
15. Pellesi L, Guerzoni S, Pini LA. Spotlight on Anti-CGRP Monoclonal
Antibodies in Migraine: The Clinical Evidence to Date. Clin
Pharmacol Drug Dev. 2017;6(6):534-547.
16. Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR.
Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The
EVOLVE-1 Randomized Clinical Trial. JAMA Neurol.2018;75(9):1080-1088.
17. Dodick DW, Silberstein SD, Bigal ME, et al. Effect of Fremanezumab
Compared With Placebo for Prevention of Episodic Migraine: A Randomized
Clinical Trial. JAMA. 2018;319(19):1999-2008.
18. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the
Preventive Treatment of Chronic Migraine. N Engl J Med.2017;377(22):2113-2122.
19. Hareendran A, Mannix S, Skalicky A, et al. Development and
exploration of the content validity of a patient-reported outcome
measure to evaluate the impact of migraine- the migraine physical
function impact diary (MPFID). Health Qual Life Outcomes.2017;15(1):224.
20. Kanaan S, Hettie G, Loder E, Burch R. Real-world effectiveness and
tolerability of erenumab: A retrospective cohort study.Cephalalgia. 2020;40(13):1511-1522.
21. Alex A, Vaughn C, Rayhill M. Safety and Tolerability of 3 CGRP
Monoclonal Antibodies in Practice: A Retrospective Cohort Study.Headache. 2020;60(10):2454-2462.
22. Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ.
Real-World Patient Experience With Erenumab for the Preventive Treatment
of Migraine. Headache. 2020;60(9):2014-2025.
23. Headache Classification Committee of the International Headache
Society (IHS) The International Classification of Headache Disorders,
3rd edition. Cephalalgia. 2018;38(1):1-211.
24. Tassorelli C, Diener HC, Dodick DW, et al. Guidelines of the
International Headache Society for controlled trials of preventive
treatment of chronic migraine in adults. Cephalalgia.2018;38(5):815-832.
25. Russo A, Silvestro M, Scotto di Clemente F, et al. Multidimensional
assessment of the effects of erenumab in chronic migraine patients with
previous unsuccessful preventive treatments: a comprehensive real-world
experience. J Headache Pain. 2020;21(1):69.
26. Silberstein S, Tfelt-Hansen P, Dodick DW, et al. Guidelines for
controlled trials of prophylactic treatment of chronic migraine in
adults. Cephalalgia. 2008;28(5):484-495.
27. Winner PK, Spierings ELH, Yeung PP, et al. Early Onset of Efficacy
With Fremanezumab for the Preventive Treatment of Chronic Migraine.Headache. 2019;59(10):1743-1752.
28. Silberstein SD, Cohen JM, Yang R, et al. Treatment benefit among
migraine patients taking fremanezumab: results from a post hoc responder
analysis of two placebo-controlled trials. J Headache Pain.2021;22(1):2.
29. Haywood KL, Mars TS, Potter R, Patel S, Matharu M, Underwood M.
Assessing the impact of headaches and the outcomes of treatment: A
systematic review of patient-reported outcome measures (PROMs).Cephalalgia. 2018;38(7):1374-1386.
30. Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and
reasons for discontinuation of prophylactic medications for episodic
migraine and chronic migraine: results from the second international
burden of migraine study (IBMS-II). Headache. 2013;53(4):644-655.
31. Lipton RB, Tepper SJ, Reuter U, et al. Erenumab in chronic migraine:
Patient-reported outcomes in a randomized double-blind study.Neurology. 2019;92(19):e2250-e2260.
32. Buse DC, Lipton RB, Hallstrom Y, et al. Migraine-related disability,
impact, and health-related quality of life among patients with episodic
migraine receiving preventive treatment with erenumab.Cephalalgia. 2018;38(10):1622-1631.
33. Barbanti P, Aurilia C, Cevoli S, et al. Long-term (48 weeks)
effectiveness, safety, and tolerability of erenumab in the prevention of
high-frequency episodic and chronic migraine in a real world: Results of
the EARLY 2 study. Headache. 2021.
34. Phillips R, Hazell L, Sauzet O, Cornelius V. Analysis and reporting
of adverse events in randomised controlled trials: a review. BMJ
Open. 2019;9(2):e024537.
35. Vernieri F, Altamura C, Brunelli N, et al. Galcanezumab for the
prevention of high frequency episodic and chronic migraine in real life
in Italy: a multicenter prospective cohort study (the GARLIT study).J Headache Pain. 2021;22(1):35.
36. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB.
Patterns of diagnosis and acute and preventive treatment for migraine in
the United States: results from the American Migraine Prevalence and
Prevention study. Headache. 2007;47(3):355-363.
37. Berger A, Bloudek LM, Varon SF, Oster G. Adherence with migraine
prophylaxis in clinical practice. Pain Pract. 2012;12(7):541-549.
38. Altman DG, Bland JM. Missing data. BMJ. 2007;334(7590):424.